ROCKVILLE, Md. & NEW YORK, August 02, 2024–(BUSINESS WIRE)–OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), a Cancer Immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company.
That’s a mouthful. Before we continue, it seems that Mouthful has interested many investors.
OSTX aims to identify lead candidates for treating osteosarcoma and other solid tumors for clinical development, regulatory approval, and commercialization. Starting with the most common genetic mutation found in Osteosarcoma, OS Therapies has identified a lead candidate in HER-2 Osteosarcoma with a goal of rapid clinical and regulatory analysis and review. This action will be immediately followed in parallel with the OST-tADC development.
The biotech is quite simple. Take OSTX’s OST-HER2 therapy as an example. This could be the reason investors rocked the graph. One of the nasty aspects of cancer is metastasis, which raises the possibility of imminent death.
This off-the-shelf immunotherapy treatment is designed to prevent metastasis, delay recurrence, kill primary tumours expressing HER2 and increase overall survival.
AOST-2121 (trial site) has enrolled 41 patients treated with OST-HER2 at 21 clinical trial sites across the United States.
Some patients remain in the active treatment stage, with the remainder in follow-up for overall survival.
The primary endpoints for the AOST-2121 study are Event Survival (‘EFS,’ defined as the absence of recurrence of primary tumour or metastasis) at 12 months and Overall Survival at 36 months with interim Overall Survival endpoints at 12 months and 24 months.
Topline EFS data, interim 1-year OS data, and additional secondary data analyses are expected to be reported in the fourth quarter of 2024.
In over 40 years, no novel therapeutic interventions have improved the clinical outcomes for patients with resected, recurrent osteosarcoma.
More?
Advances in the treatment of osteosarcoma have improved the outlook for this cancer.
After treatment for osteosarcoma, people sometimes face late effects from the vital therapies used to control the cancer.
Healthcare professionals often suggest lifelong monitoring for side effects after treatment.
OSTEOSARCOMA
RARE BONE CANCER
ATTACKS KIDS AND ADULTS
AGGRESSIVE AND RECURS
OS THERAPIES WERE CREATED TO IDENTIFY POTENTIAL TREATMENTS FOR OS THAT NEEDED ASSISTANCE PROVING THEY WORKED AND COULD BE BROUGHT TO PATIENTS.
Advances in the treatment of osteosarcoma have improved the outlook for this cancer.
After treatment for osteosarcoma, people sometimes face late effects from the vital therapies used to control the cancer.
Healthcare professionals often suggest lifelong monitoring for side effects after treatment.
High grade: Most osteosarcomas are high grade, meaning they will probably grow and spread quickly if not treated. The usual treatment for these cancers is as follows:
Biopsy to establish the diagnosis
Chemotherapy (chemo), usually for about ten weeks
Surgery to remove the tumour, preferably by the same surgeon who did the biopsy. If cancer is found at the edge of the surgery specimen (meaning some tumour might have been left behind), a second surgery might be done to try to remove any remaining cancer. Radiation therapy might be given to the area as well.
More chemotherapy (for up to a year). If the initial chemotherapy killed most of the cancer cells, the same drugs are often given again after surgery. If the initial chemotherapy didn’t work well, different drugs might be tried (although not all doctors agree that switching drugs is needed).
Investors have keyed into OSTX’s unique and deeply important research. The treatment for bone cancer is impressive, as it is aimed at a rare disease. Other unique therapies deal with solid tumours in various diseases.
Remember this, if nothing else: therapy OST-HER2, this off-the-shelf immunotherapy treatment, is designed to prevent metastasis, delay recurrence, kill primary tumours expressing HER2 and increase overall survival.
